● Recruiting

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Small Lymphocytic Lymphoma · CLL/SLL · Sponsor: Zulfa Omer

PhasePhase 2

Planned participants34

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

This description comes directly from the study's public registry record.

Talk to the study team

UCCC Clinical Trials Office · 513-584-7698 · cancer@uchealth.com

Zulf Omer, MD

Always discuss trial participation with your own doctor first.

Locations (1)

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06978088